Showing 221 - 240 results of 65,206 for search '(( 5 cm decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.07s Refine Results
  1. 221

    All data points from Fig 9. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  2. 222

    All data points from Fig 7. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  3. 223

    All data points from Fig 6. by Sara Hijazi (21656615)

    Published 2025
    “…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”
  4. 224

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
  5. 225
  6. 226

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  7. 227
  8. 228
  9. 229
  10. 230
  11. 231
  12. 232
  13. 233
  14. 234
  15. 235
  16. 236
  17. 237
  18. 238
  19. 239

    Decreased MBP levels in the brain in <i>Large</i><sup><i>myd/myd</i></sup> mice. by Shigefumi Morioka (8893511)

    Published 2020
    “…<b>B,</b> Whole-brain lysates of P7 control and <i>Large</i><sup><i>myd/myd</i></sup> mice (<i>n</i> = 5) were obtained for MBP immunoblotting. Decreased expression levels of MBP were observed in <i>Large</i><sup><i>myd/myd</i></sup> mice compared with those in control mice. …”
  20. 240